Irreversible electroporation for treating prostate cancerStatus:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: 1 February 2023
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerStatus:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: 7 February 2023
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 11 October 2023
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID 5103]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC